AmerisourceBergen and our global pharmaceutical healthcare businesses are monitoring the ongoing spread of the novel COVID-19 coronavirus.
As an active participant in the global pharmaceutical supply chain, we’re engaged with government and healthcare officials as these agencies and experts closely monitor the spread of COVID-19. We have business continuity plans that include our global workforce and our teams are in daily communications with manufacturers, monitoring inventory levels and customer purchasing behavior for any potential impact to the product supply chain.
We will continue to be highly engaged as the situation evolves on a day-to-day basis and will post updates here for our customers.
Partnering to distribute EUA approved COVID-19 therapies
AmerisourceBergen is working with U.S. Department of Health and Human Services (HHS) in distributing COVID-19 therapies approved for Emergency Use Authorization (EUA).